ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1488	National Cancer Institute	Html	en	Metastatic Squamous Neck Cancer With Occult Primary Treatment (PDQ®)–Health Professional Version	Metastatic squamous neck cancer with occult primary occurs when squamous cell cancer spreads to lymph nodes in the neck from an undetectable primary tumor. Treatment includes surgery and radiation therapy. Learn about the diagnosis, survival, staging, and treatment of these tumors.	primary site. 0.436234 moderately differentiated tumors 0.539497 Thyroid function testing 0.46762 massive homolateral adenopathy 0.465434 EBV genomic material 0.535385 metastatic carcinoma 0.482369 lymph node dissection 0.549764 probable primary site 0.571551 germ cell tumor 0.575226 PDQ cancer information 0.618029 cervical lymph nodes. 0.554105 poorly differentiated tumors 0.545473 entire thyroid gland 0.457464 cancer information summary 0.595141 Primary tumors 0.485135 palpable tumor 0.472764 breast cancer prevention 0.4696 adequate neck dissection 0.527836 primary physician 0.522652 patients 0.45154 poorly differentiated tumor 0.752934 fine-needle aspiration biopsy 0.484684 epstein-barr virus 0.506145 NCI PDQ cancer 0.504517 lower neck 0.447545	radiation therapy 0.728398 cervical nodal tissue 0.52026 squamous carcinoma 0.531992 magnetic resonance imaging 0.467707 neck mass 0.432409 DNA amplification 0.492378 metastatic squamous cell 0.564542 neck primary site 0.62075 germ cell malignancies 0.487658 metastatic lymph node 0.63625 overt nasopharyngeal carcinoma. 0.485019 cervical lymph node 0.754988 obvious metastatic disease 0.554252 polymerase chain reaction 0.487648 cervical node metastases 0.558588 Squamous carcinomas 0.45824 external-beam radiation therapy 0.502847 Periodic Acid Schiff 0.471213 unknown primary 0.44413 platinum-based combination chemotherapy 0.478329 undifferentiated carcinoma 0.456062 neck tumors 0.464529 occult primary tumor 0.948651 lymph node metastases 0.623031	CLICK HERE
1526	National Cancer Institute	Html	en	Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of nasopharyngeal cancer.	clinical trial 0.341084 treatment 0.278725 clinical trial search 0.201632 cancer clinical trials 0.224875 lymph nodes 0.503913 radiation therapy 0.653094	National Cancer Institute 0.229813 cancer 0.952582 nasopharyngeal cancer 0.779979 clinical trials 0.675026 affected lymph nodes 0.35443	CLICK HERE
1692	National Cancer Institute	Html	en	Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Patient Version	Expert-reviewed information summary about the use of nutrition and dietary supplements for reducing the risk of developing prostate cancer or for treating prostate cancer.	advanced prostate cancer 0.462339 anticancer effects 0.463801 clinical trial search 0.473734 green tea extract 0.477186 medical condition 0.458517 PSA levels 0.542556 clinical trials 0.664244 hormone-refractory prostate cancer 0.474056 U.S. Food 0.502589 early prostate cancer 0.465338 placebo 0.450024 laboratory studies 0.464618 prostate cancer cells 0.484177 prostate cancer risk 0.582265 food products 0.450637 prostate specific antigen 0.47312 prostate cancer patients 0.605367 population studies 0.543492 Prostate cancer deaths 0.462733 effects 0.499767 prostate cancer rates 0.456143 lycopene 0.466211 prostate cancers 0.457956 treatment 0.466735 study 0.482571	prostate cancer prevention 0.485364 androgen-independent prostate cancer 0.473958 tumor cells 0.455948 United States 0.574219 recurrent prostate cancer 0.457873 Drug Administration 0.504644 NCI-supported cancer 0.451146 products 0.463319 high-grade prostate cancer 0.459874 selenium 0.479361 dietary supplements 0.709022 studies 0.641892 general information 0.454636 green tea 0.628302 animal studies 0.638323 professional version 0.461561 low-grade prostate cancer 0.456901 label claims 0.456268 mixed results 0.4651 prostate cancer 0.981204 cancer clinical trials 0.48181 selenium supplements 0.463263 aggressive prostate cancer 0.460411 Laboratory/Animal/Preclinical Studies section 0.507788	CLICK HERE
1738	National Cancer Institute	Html	en	Angiogenesis Inhibitors	A fact sheet that describes the process of eliminating the blood supply to tumors. Lists the cancers in which this approach is being tested.	downstream signaling pathways 0.352285 cancer treatments 0.343078 endothelial cells 0.425301 normal endothelial cells 0.371999 ongoing clinical trials 0.354207 tumor blood vessels 0.37481 chemical signals 0.419755 Drug Administration 0.362362 nearby normal cells 0.358821 endothelial growth factors 0.369707 cancer cells 0.356859 VEGF receptor 0.345762 angiogenesis inhibitors 0.944406 inhibiting effects 0.333711 Finding NCI-Supported Clinical 0.352444 antiangiogenic agents 0.332621 synthetic angiogenesis inhibitors 0.552673 angiogenesis pathways 0.444579 new blood vessels 0.642431 endothelial growth factor 0.370427 rare side effects 0.352056 tumor-vascular disrupting agents 0.351163 tumor angiogenesis 0.466745 nci-supported clinical trials 0.386702	treatment clinical trials 0.356002 blood vessel growth 0.362373 metastatic colorectal cancer 0.362717 tumor growth 0.335181 clinical trials 0.464552 tumor cells 0.336152 U.S. Food 0.362379 renal cell cancer 0.360541 VEGF 0.349952 blood vessels 0.736003 angiogenesis inhibitor therapy 0.559395 blood vessel formation 0.363763 non-small cell lung 0.351539 normal body processes 0.348332 kidney cancer 0.365728 NCI Contact Center 0.349609 tumors 0.369989 cancer clinical trials 0.389068 blood supply 0.372039 human cancer 0.334753 conventional anticancer drugs 0.349958 cancer 0.433974 growth 0.373337	CLICK HERE
1848	National Cancer Institute	Html	es	Tratamiento del cáncer de piel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de piel.	Compton CC 0.427006 ángulo nariz-mejilla 0.312075 Cutaneous squamous 0.410175 criocirugía frente 0.310658 skin cancers 0.337834 señalización tipo erizo 0.316126 basal-cell carcinoma 0.31436 American Cancer Society 0.31065 Casciato DA 0.3104 7th ed 0.425796 Dermatol Surg Oncol 0.322688 TFD frente 0.31135 cutaneous carcinomas 0.448478 Mohs surgery is 0.310939 Plast Reconstr Surg 0.318551 carcinomas cutáneos 0.316845 Estados Unidos 0.319384 Natl Cancer Inst 0.311163 human papillomavirus infection 0.320874 CCE invasor 0.312649 Euros frente 0.310849 N2a Metástasis 0.310265 cell carcinomas 0.926899 escisión frente 0.315633 Arch Dermatol 0.342458	Carcinoma apocrino 0.319357 uncomplicated basal cell 0.313087 Invest Dermatol 0.31893 Mohs micrographic surgery 0.311178 micosis fungoide 0.313548 Cancer Staging Manual 0.594205 recidivas locales 0.316877 PDQ Tratamiento 0.321192 New York 0.409746 Day CL Jr 0.315276 clasificación tnm 0.310941 células escamosas cutáneos 0.311636 Dermatol Surg 0.324225 Byrd DR 0.419056 T2b Tumor 0.314992 Karagas MR 0.311264 basal cell carcinomas 0.750035 American Joint Committee 0.344157 párpadoa aReproducción 0.326393 tumor fotosensibilizadores 0.313881 Tis Carcinoma 0.334823 Carcinoma arising 0.318249 AJCC Cancer Staging 0.604512 Edge SB 0.427178	CLICK HERE
2006	National Cancer Institute	Html	es	Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y el paraganglioma.	glándula tiroides 0.609278 glándulas suprarrenales ayuda 0.631749 siguientes procedimientos 0.696393 siguientes aspectos 0.575361 Neurofibromatosis tipo 0.579395 siguientes síndromes 0.595261 vía oral 0.53652 rayos x 0.649118 tumores neuroendocrinos 0.602024 National Cancer Institute 0.520886 paraganglioma causa efectos 0.753898 siguientes riesgos 0.518888 endocrina múltiple tipo 0.630502 feocromocitoma hereditario 0.929917	Instituto Nacional 0.540854 PDQ Tratamiento 0.549585 insuficiencia suprarrenal aguda 0.595836 Mucha sudación 0.56538 partes distantes 0.527507 Physician Data Query 0.586955 siguientes situaciones 0.586373 siguientes características 0.581278 von hippel-lindau 0.636326 TEP -FDG 0.553345 enfermedad.ampliar paraganglioma 0.655429 Períodos súbitos 0.521079 siguientes medicamentos 0.565161 siguientes pruebas 0.590766	CLICK HERE
2045	National Cancer Institute	Html	es	Exámenes de detección del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de ovario, de trompas de Falopio y primario de peritoneo.	Obstet Gynecol 0.429928 United Kingdom Collaborative 0.409268 Bast RC Jr 0.42202 Jacobs IJ 0.404314 ensayo ca-125 0.406196 randomised controlled 0.404882 ovarian cancer algorithm 0.442917 término cáncer 0.410224 Longitudinal screening algorithm 0.406983 American Cancer Society 0.41643 gynecologic cancers 0.414338 Cancer Screening Randomized 0.428277 ensayo plco 0.448316 Kingdom Collaborative Trial 0.414212 ecografía transvaginal 0.498268 serum ca-125 levels 0.405779 Instituto Nacional 0.405706 screening trial specimens 0.40956 ovarian cancer 0.962069 grupo control 0.404575 PDQ Exámenes 0.408591 uk collaborative trial 0.420355 ovarian carcinoma 0.410371 Estados Unidos 0.412447 Natl Cancer Inst 0.419302	Randomized Controlled Trial 0.413244 Partridge E 0.417834 CA-125 velocity 0.404292 PDQ Prevención 0.409813 Gynecol Oncol 0.414371 detección simultáneos 0.410338 SEER Cancer Statistics 0.408582 using transvaginal sonography 0.404548 cohort study 0.404541 marcador sérico ca-125 0.406906 Cancer Facts 0.408569 controlled trial 0.421989 National Cancer Institute 0.418053 Gynecologic Cancer Predisposition 0.409737 collaborative trial 0.433295 Shizuoka Cancer Registry 0.409677 PDQ Genetics 0.404479 Gynecol Cancer 0.409511 cancer screening trial 0.473823 PLCO trial with 0.406621 Screening Randomized Controlled 0.416835 Buys SS 0.413143 ovarian cancer screening 0.679966 mujeres morirán 0.405822	CLICK HERE
2958	National Cancer Institute	Html	en	Making a Quit Plan	Planning ahead improves your chances of quitting smoking for good. Follow these steps to create your own individual quit plan.	health care provider 0.682085 common smoking reminders 0.549 ashtrays 0.452031 easy steps 0.487737 NRT 0.496038 healthy snacks 0.472018 energy level 0.475958 special treat 0.473544 word QUIT 0.556414 nicotine replacement therapy 0.840728 items—like straws 0.475777 quit plan 0.979663 favorite songs 0.473638 triggers 0.466512 list 0.464107 text message 0.469947 friends 0.440731 online chat 0.467529 chances 0.434282 young adults 0.470223 cigarettes 0.452193 monitor progress 0.465509 big accomplishment 0.488463 United States 0.472032 smoke breaks 0.469072	regular exercise 0.473275 National Cancer Institute 0.530065 NCI LiveHelp page 0.544024 text messaging service 0.527129 craving 0.4367 good mood 0.477991 cravings 0.511271 Smokefree Apps help 0.573957 movie night 0.475119 Nicotine withdrawal 0.548423 Practice deep breathing 0.541377 cigarette money 0.475711 huge achievement 0.482604 Eastern Time 0.480147 nicotine gum 0.500974 different pleasure 0.478743 cigarette butts 0.473635 withdrawal symptoms 0.585184 activities 0.427718 smokefree milestone 0.520259 time 0.49243 online calendars 0.483411 smoking cessation counselor 0.535799 family 0.428198	CLICK HERE
16683	National Cancer Institute	Html	es	714-X (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del 714-X como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Alternative Medicine Confronts 0.349 Task Force 0.681834 Rock Forest 0.4465 Cancer Research Initiative 0.920081 Radiosensitizing effect 0.323708 but not 0.32369 Goel HC 0.323157 Alternative Therapeutic 0.727518 Bacteria Cause Cancer 0.362108 Unconventional therapies 0.71198 Breast Cancer Research 0.913503 saccharin-LiCl conditioned stimulus 0.34146 Roa AR 0.322774 transplantable mammary 0.323668 Instituto Nacional 0.49296 Pharmacol Biochem Behav 0.342417 Pavlovian conditioning 0.324132 PDQ 714-X 0.384196 posibles efectos 0.32412 Estados Unidos 0.547224 Canadian Breast Cancer 0.923206 for bacteria as 0.342644 vía nasal 0.324957 Purohit A 0.322533 New York University 0.333776	alcanfor mejora 0.352671 Conditioned enhancement 0.324112 linfoma caninos 0.323743 CERBE Distribution 0.468077 Solvason HB 0.367895 Hiramoto RN 0.325133 new approach 0.322794 empresa distribuidora 0.324674 National Cancer Institute 0.431242 Hiramoto NS 0.502986 vitamina b12 0.324597 New York 0.3535 accessed april 0.467486 Neurosci Res 0.325453 numerosos oligoelementos 0.325391 Physician Data Query 0.337084 Hess DJ 0.368799 libre uso 0.325033 linfosarcoma murinos 0.323938 Ghanta VK 0.432317 cartílago bovino 0.325426 killer cell activity 0.342736 response to yc8 0.339588 Soong SJ 0.323559	CLICK HERE
16843	National Cancer Institute	Html	en	Massachusetts General Hospital and Harvard Univeristy — Imaging of Nanotherapeutic Drug Action	In vivo imaging analyses of therapeutic nanoparticles (TNP), addressing key questions on nanoparticle distribution (pharmacokinetics, PK) and cellular response (pharmacodynamics, PD).	nanoparticle distribution 0.841511 enhanced MR imaging 0.924949 biological understanding 0.766676 Alliance members 0.763245 M.D. 0.664358 vivo imaging analyses 0.983793 Claudio Vinegoni 0.829503 Cesar Castro 0.816804 cancer cells 0.772225 NCI Alliance 0.790962 Ph.D 0.666483 project team 0.768015 considerable proportion 0.780069 clinical data 0.766134 recent developments 0.775301 multimodality imaging 0.800032 larger number 0.783733 affinity ligands 0.782978 cancer nanotechnology questions 0.94124 Ralph Weissleder 0.799712 TNP 0.654222 free survival 0.789955 vivo imaging technologies 0.994916 nano-encapsulated chemotherapeutics 0.788661	recent feasibility studies 0.924078 lower toxicity 0.785357 cancer members 0.792525 molecular diagnostics 0.779336 new strategy 0.77113 following questions 0.766532 new constructs 0.797665 new biological insight 0.926895 vivo setting 0.83945 tumoral accumulation 0.816621 temporal heterogeneity 0.803444 key questions 0.775023 future interactions 0.756886 efficacy 0.740414 tumoral myeloid cells 0.915593 Principal Investigators 0.797013 tumor cell accumulation 0.959124 therapeutic nanoparticles 0.774355 molecular / cell 0.763144 occasionally improved progression 0.958519 Mikael Pittet 0.837942 cancer biology 0.77172 Alliance projects 0.764335	CLICK HERE